Skip to main content
. 2022 Sep 10;36(6):701–715. doi: 10.1007/s40259-022-00555-5
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) can attenuate acute respiratory distress syndrome (ARDS) due to their anti-inflammatory and cell repair properties.
Biotechnological processing and appropriate administration routes can further improve the therapeutic effect of MSC-EVs and overcome their limitations.